TPG Biotech has now invest almost $28m in the skin disorder specialist, which will use the cash to advance clinical trials for its lead product.

Trevi Therapaeutics, a US-based developer of treatments for skin disease, has secured $25m in series B financing in a round led by TPG Biotech, the life science venture fund owned by private equity firm TPG.

TPG Biotech, which Trevi said has funded it since inception, invested $15m at first close, having previously committed $12.8m in equity.

Trevi is working on treatments for two skin conditions, uremic pruritus and prurigo nodularis. It intends to use the funding to support crucial trials…